GeminIQ Website Logo

Viewing ACAD free

Subscribe for full history, 90+ metrics, screener, watchlist...

ACADIA PHARMACEUTICALS INC

ACAD

Companies in Pharmaceutical Preparations

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Cash And Cash Equivalents At Carrying Value
28217825825421832015517720518998108
Available For Sale Securities Debt Securities Curr…
569642589508464436410324266250248267
Accounts Receivable Net Current
135121116108106999810495989382
Interest Receivable Current
13272412861275422
Prepaid Expense Current
656061535356524643393824
Assets Current
1,0961,0621,076961871938788729675616499493
Property Plant And Equipment Net
1584434444555
Operating Lease Right Of Use Asset
464750515147445254525152
Finite Lived Intangible Assets Net
106109112114117120106108110656768
Restricted Cash Noncurrent
889999966668
Inventory For Long Term Contracts Or Programs
81777784807026155555
Deferred Income Tax Assets Net
250250---0------
Other Assets Noncurrent
4432100000011
Assets
1,6051,5641,3311,2261,1321,188977914855749633643
Liabilities And Stockhold…
Accounts Payable Current
121122201816192019181219
Accrued Liabilities Current
293266335310284379325318311237197169
Liabilities Current
306277357330303395344338331254210188
Operating Lease Liability Noncurrent
394143454542404749484850
Other Liabilities Noncurrent
13191429201815121115139
Liabilities
357337413403367455400397391317270247
Stockholders Equity
Preferred Stock Value
000000000000
Common Stock Value
000000000000
Additional Paid In Capital Common Stock
3,0583,0393,0032,9812,9502,9372,9242,8982,8792,8632,8392,808
Retained Earnings Accumulated Deficit
-1,810-1,813-2,087-2,159-2,185-2,204-2,348-2,381-2,414-2,431-2,477-2,411
Accumulated Other Comprehensive Income Loss Net Of…
-1110001-0-00-0-1
Stockholders Equity
1,2481,227917822765733577517464432362396
Liabilities And Stockholders Equity
1,6051,5641,3311,2261,1321,188977914855749633643
Preferred Stock Par Or Stated Value Per Share
000000000000
Preferred Stock Shares Authorized
555555555555
Preferred Stock Shares Issued
000000000000
Preferred Stock Shares Outstanding
000000000000
Common Stock Par Or Stated Value Per Share
000000000000
Common Stock Shares Authorized
225225225225225225225225225225225225
Common Stock Shares Issued
171170169169167167166166165165164163
Shares Outstanding
171170169169167167166166165165164163

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-3.99%12.23%10.11%---------
202527.41%30.66%37.33%6.52%-13.73%-9.75%15.66%27.58%23.97%-15.83%-10.02%-13.15%
2024-0.72%6.84%25.84%9.29%3.43%-5.47%-5.12%-1.45%8.55%-13.19%-23.84%15.10%
202314.20%11.14%34.76%5.15%-13.38%-18.53%-7.40%30.45%13.38%-24.42%-29.18%-37.73%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
3.59
3.83
3.02
2.91
2.88
2.38
2.29
2.16
2.04
2.42
2.38
2.62
Quick Ratio
3.38
3.62
2.85
2.75
2.70
2.24
2.14
2.02
1.91
2.27
2.20
2.49
Working Capital
790.49M
785.00M
719.84M
630.53M
568.41M
543.45M
444.34M
391.07M
344.70M
361.87M
289.57M
304.69M
Leverage & Debt
Debt to Equity
0.29
0.27
0.45
0.49
0.48
0.62
0.69
0.77
0.84
0.73
0.75
0.62
Interest Coverage TTM
2.54
3.30
7.93
8.24
8.43
9.07
4.84
1.10
-0.24
-4.26
-9.59
-8.93
Debt Ratio
0.22
0.22
0.31
0.33
0.32
0.38
0.41
0.43
0.46
0.42
0.43
0.38
Efficiency & Turnover
Asset Turnover TTM
0.80
0.78
0.91
0.95
1.00
0.99
1.15
1.14
1.08
1.09
1.02
0.88
Days Sales Outstanding TTM
40.17
37.50
37.31
37.83
36.72
37.54
37.51
38.03
36.02
40.31
42.90
49.63
Receivables Turnover TTM
9.09
9.73
9.78
9.65
9.94
9.72
9.73
9.60
10.13
9.05
8.51
7.35
Per Share Metrics
Diluted EPS TTM
2.18
2.30
1.53
1.32
1.37
1.36
0.77
0.18
-0.01
-0.37
-0.91
-0.67
Free Cash Flow Per Share TTM
0.67
0.04
0.59
0.53
0.30
0.95
1.22
0.49
0.14
-0.14
-0.81
-0.45
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Gross Profit Margin TTM
91.47%
91.69%
91.92%
91.97%
92.04%
91.46%
91.61%
91.72%
92.27%
94.27%
95.86%
97.52%
Operating Profit Margin TTM
7.39%
9.78%
23.01%
23.24%
23.58%
24.10%
12.08%
2.56%
-0.56%
-10.10%
-24.43%
-23.14%
Net Profit Margin TTM
34.30%
36.49%
24.94%
21.80%
22.97%
23.64%
13.83%
3.43%
-0.21%
-8.44%
-23.55%
-20.12%
Growth Metrics
Net Revenue Growth (1Y)
9.93%
11.87%
12.69%
14.41%
22.42%
31.85%
47.06%
61.65%
56.43%
40.45%
23.54%
7.51%
Net Income Growth (1Y)
64.12%
72.66%
103.24%
626.84%
-13,484.97%
-469.50%
-186.36%
-127.58%
-98.83%
-71.62%
-31.53%
-45.84%
EPS Growth (1Y)
60.55%
69.96%
99.79%
616.99%
-13,323.68%
-465.27%
-185.45%
-127.23%
-98.85%
-71.99%
-32.53%
-46.44%
Valuation Metrics
P/E TTM
10.10
11.50
13.80
16.29
12.11
13.43
19.86
88.02
-1,781.94
-83.69
-23.00
-35.33
P/B TTM
3.04
3.66
3.93
4.40
3.62
4.15
4.42
5.21
6.57
11.88
9.45
9.89
P/S TTM
3.47
4.20
3.44
3.55
2.78
3.17
2.75
3.02
3.74
7.06
5.42
7.11
Market Cap
3.80B
4.50B
3.60B
3.62B
2.77B
3.04B
2.55B
2.69B
3.05B
5.13B
3.42B
3.91B
Enterprise Value
3.51B
4.32B
3.34B
3.37B
2.55B
2.72B
2.40B
2.51B
2.84B
4.94B
3.32B
3.81B
Calculated Values
Free Cash Flow TTM
113.59M
6.31M
98.97M
88.25M
49.60M
157.20M
202.66M
80.48M
23.66M
-23.35M
-132.59M
-74.31M
Net Debt
-282.21M
-177.70M
-258.00M
-253.64M
-217.70M
-319.59M
-155.15M
-177.13M
-204.75M
-188.66M
-98.19M
-107.94M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-06-26Sale
Owner: Kihara, James
Title: PRINCIPAL ACCOUNTING OFFICER
Shares: 11,421
Price/Share: $26.08
Value: $297,859.68
Shares Owned: 13,088
Relationship: Officer
Ownership: Direct
2026-05-26Sale
Owner: Kihara, James
Title: PRINCIPAL ACCOUNTING OFFICER
Shares: 5,401
Price/Share: $21.18
Value: $114,393.18
Shares Owned: 24,509
Relationship: Officer
Ownership: Direct
2026-05-04Sale
Owner: Schneyer, Mark C.
Title: EVP, CHIEF FINANCIAL OFFICER
Shares: 3,506
Price/Share: $21.79
Value: $76,395.74
Shares Owned: 66,145
Relationship: Officer
Ownership: Direct
2026-05-04Sale
Owner: Kihara, James
Title: PRINCIPAL ACCOUNTING OFFICER
Shares: 1,332
Price/Share: $21.79
Value: $29,024.28
Shares Owned: 29,129
Relationship: Officer
Ownership: Direct
2026-04-07Sale
Owner: Kihara, James
Title: PRINCIPAL ACCOUNTING OFFICER
Shares: 1,030
Price/Share: $22.20
Value: $22,866.00
Shares Owned: 27,865
Relationship: Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
95.39%
Inst. Shares: 162,659,813
Shares Outstanding: 170,517,000
2025-12-31
97.50%
Inst. Shares: 164,142,601
Shares Outstanding: 168,356,000
2025-09-30
97.68%
Inst. Shares: 164,913,463
Shares Outstanding: 168,836,000
2025-06-30
99.62%
Inst. Shares: 167,196,376
Shares Outstanding: 167,827,000
2025-03-31
101.27%
Inst. Shares: 168,928,566
Shares Outstanding: 166,808,000

ACADIA PHARMACEUTICALS INC (ACAD) — SEC Financial Statements & Analysis

ACADIA PHARMACEUTICALS INC (ACAD) is a pharmaceutical preparations company, incorporated in DE. ACADIA PHARMACEUTICALS INC trades on Nasdaq as: ACAD. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ACADIA PHARMACEUTICALS INC reported a 9.93% year-over-year revenue growth, a Gross Profit Margin of 91.47% (TTM), a Debt-to-Equity ratio of 0.29x, a Price-to-Sales (P/S) ratio of 3.47x (TTM), a Price-to-Book (P/B) ratio of 3.04 (TTM), at a market cap of $3.80B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
9.93%
Gross Profit Margin TTM
91.47%
Debt To Equity
0.29x
P/S TTM
3.47x
P/B TTM
3.04
Market Cap
$3.80B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ACADIA PHARMACEUTICALS INC in?

ACADIA PHARMACEUTICALS INC (ACAD) operates in the Pharmaceutical Preparations industry.

What is ACAD's market cap?

ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of $3.80B as of 2026-03-31.

What is ACAD's P/E ratio?

ACADIA PHARMACEUTICALS INC (ACAD)'s trailing twelve month P/E ratio is 10.10x as of 2026-03-31.

What exchange does ACAD trade on?

ACADIA PHARMACEUTICALS INC (ACAD) trades on the Nasdaq.

Where is ACADIA PHARMACEUTICALS INC incorporated?

ACADIA PHARMACEUTICALS INC is incorporated in DE.

Research Faster.
Invest Smarter.

ACADIA PHARMACEUTICALS INC (ACAD) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 90+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.